Paul T. Quinlan, General Counsel of Oruka Therapeutics, Inc. (NASDAQ:ORKA), filed a Form 4 on September 21, 2026, reporting the exercise of an employee warrant and the sale of common stock under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Warrant exercise: Quinlan exercised an employee warrant to acquire 10,000 shares of common stock at an exercise price of $7.80 per share on September 21, 2026.
  • Shares sold: A total of 10,000 shares were sold across four tranches on September 21, 2026, at weighted average prices ranging from $92.3689 to $95.3115 per share.
  • Rule 10b5-1 plan: According to the filing, all sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
  • Remaining ownership: Following all reported transactions, Quinlan directly beneficially owned 29,995 shares of common stock.
  • Derivative securities: After the warrant exercise, Quinlan retained 79,996 employee warrants, directly held, with an expiration date of July 14, 2034.

Warrant Exercise and Planned Share Sales by Oruka Therapeutics General Counsel

According to the Form 4 filing, Paul T. Quinlan, serving as General Counsel of Oruka Therapeutics, Inc., conducted several transactions in the company's common stock on September 21, 2026. The filing indicates that Quinlan first exercised an employee warrant covering 10,000 shares at a conversion price of $7.80 per share, with the warrant carrying an expiration date of July 14, 2034. The filing notes the warrant vests as to 1/4 of the underlying shares on April 30, 2025, and as to 1/48 of the underlying shares monthly from April 30, 2025.

Following the warrant exercise, the filing reports four separate sale transactions, all executed under the Rule 10b5-1 trading plan adopted on May 15, 2026. The tranches were: 2,900 shares at a weighted average price of $92.3689 (individual transaction prices ranging from $91.87 to $92.78); 3,832 shares at a weighted average price of $93.3173 (ranging from $92.89 to $93.80); 601 shares at a weighted average price of $94.4426 (ranging from $94.02 to $94.98); and 2,667 shares at a weighted average price of $95.3115 (ranging from $95.05 to $95.75). The filing notes all weighted average prices are subject to full price-by-price detail available upon request to Oruka Therapeutics, any security holder, or SEC staff.

After all transactions, the filing reports Quinlan directly held 29,995 shares of common stock and 79,996 employee warrants. The transactions were filed on the date of earliest transaction, September 21, 2026, and the filing was made by one reporting person. The form also confirms the box indicating a Rule 10b5-1(c) plan was checked.

What Was Disclosed

The filing disclosed the exercise of 10,000 employee warrants at $7.80 per share and the sale of 10,000 shares of Oruka Therapeutics common stock in four tranches at weighted average prices between $92.3689 and $95.3115, all under a pre-established Rule 10b5-1 trading plan.